Peritoneal dialysis solutions with polypeptides
AssigneeBaxter International Inc.
InventorsLeo Martis, Ron Burke, Dirk Faict
Life of this patent
Estimating the term…
Abstract
The present invention provides an improved dialysis solution. The improved dialysis solution provides for the use of specific polypeptides as an osmotic agent with an additional osmotic agent such as dextrose. To this end, the present invention provides, in an embodiment, a peritoneal dialysis solution comprising as osmotic agents approximately 0.25 to about 4.0% (w/v) polypeptides and approximately 0.5% to about 4.0% (w/v) dextrose. The polypeptides have well defined characteristics.
Claims3
A two part peritoneal dialysis solution designed to be mixed prior to infusion into a patient comprising:
- a first part housed in a first structure including dextrose;
- a second part housed in a second structure including approximately 0.25 to about 4.0% (w/v) polypeptides;
- and
- including in either the first or the second structure a sufficient amount of the following ingredients so when the first part and second part are mixed, the following is provided:
- 120 to about 150 (mEq/L) sodium;
- 80.0 to about 110.0 (mEq/L) chloride;
- 0.0 to about 5.0 (mEq/L) lactate;
- 0.0 to about 45.0 (mEq/L) bicarbonate;
- 0.0 to about 4.0 (mEq/L) calcium;
- and 0.0 to about 4.0 (mEq/L) magnesium, wherein not more than approximately 0.10% of the polypeptides has a molecular weight of greater than 1200, not more than approximately 25% of the polypeptides has a molecular weight of less than 400, and the weight average of polypeptides is within the range of approximately 400 to about 900 daltons.
A two part peritoneal dialysis solution designed to be mixed prior to infusion into a patient comprising:
- a first part housed in a first structure including dextrose;
- a second part housed in a second structure including approximately 0.25 to about 8.0% (w/v) polypeptides having a molecular weight average of approximately 400 to about 900 daltons;
- and
- including in either the first or the second structure a sufficient amount of the following ingredients so when the first part and second part are mixed, the following is provided:
- 120 to about 150 (mEq/L) sodium;
- 80.0 to about 110.0 (mEq/L) chloride;
- 0.0 to about 5.0 (mEq/L) lactate;
- 0.0 to about 45.0 (mEq/L) bicarbonate;
- 0.0 to about 4.0 (mEq/L) calcium;
- and 0.0 to about 4.0 (mEq/L) magnesium, wherein the first and second structures are two separate chambers of a single container.
A two part peritoneal dialysis solution designed to be mixed prior to infusion into a patient comprising:
- a first part housed in a first structure, the first part including approximately 1.0 to about 8% (w/v) dextrose and a pH of approximately 4.0 to about 5.5;
- a second part housed in a second structure, the second part including approximately 0.5 to about 8.0% (w/v) polypeptides and a pH of approximately 6.0 to about 7.5 wherein not more than approximately 0.10% of the polypeptides have a molecular weight of greater than 1200, wherein not more than approximately 25% of the polypeptides have a molecular weight of less than 400, and wherein the weight average of polypeptides is within the range of approximately 400 to about 900 daltons;
- and
- including in either the first or the second structure a sufficient amount of the following ingredients so when the first part and second part are mixed, the following is provided:
- 120 to about 150 (mEq/L) sodium;
- 80.0 to about 110.0 (mEq/L) chloride;
- 0.0 to about 5.0 (mEq/L) lactate;
- 0.0 to about 45.0 (mEq/L) bicarbonate;
- 0.0 to about 4.0 (mEq/L) calcium;
- and 0.0 to about 4.0 (mEq/L) magnesium.
Dependencies are inferred from the claim text.